The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation. 

Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

The nonprofit patient-safety organization says the list “reflects our judgment about which risks should be given attention now to help care providers, as well as device manufacturers, prioritize their patient safety efforts.”

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

Buzzworthy developments of the past few days.

Members of C-suites around the world are making room for a new teammate: the CAIO. In healthcare, some organizations are hiring for the even more specialized position of CHAIO, for chief health AI officer.